Patents by Inventor Travis Michael Whitfill

Travis Michael Whitfill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11850267
    Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: December 26, 2023
    Assignee: Azitra Inc
    Inventor: Travis Michael Whitfill
  • Patent number: 11773154
    Abstract: The present disclosure provides, inter alia, engineered microbes expressing recombinant LEKTI domains that are effective to treat or ameliorate the symptoms of Netherton Syndrome. In certain embodiments, compositions, methods, and kits are provided comprising LEKTI domain expressing microbes.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 3, 2023
    Assignee: Azitra Inc
    Inventors: Travis Michael Whitfill, Azim Momin Munivar
  • Publication number: 20220112455
    Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
    Type: Application
    Filed: May 14, 2021
    Publication date: April 14, 2022
    Inventors: Travis Michael Whitfill, Ming-De Deng, David Richard Dodds, Alexander Tikhonov
  • Publication number: 20210379120
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 9, 2021
    Inventors: Azim Momin Munivar, Travis Michael Whitfill
  • Patent number: 11041217
    Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: June 22, 2021
    Assignee: Azitra Inc
    Inventors: Travis Michael Whitfill, Ming-De Deng, David Richard Dodds, Alexander Tikhonov
  • Publication number: 20210121504
    Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 29, 2021
    Inventor: Travis Michael Whitfill
  • Publication number: 20210070823
    Abstract: The present disclosure provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of skin diseases, in particular atopic dermatitis.
    Type: Application
    Filed: April 3, 2020
    Publication date: March 11, 2021
    Inventor: Travis Michael Whitfill
  • Patent number: 10702558
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 7, 2020
    Assignee: Azitra Inc
    Inventors: Azim Momin Munivar, Travis Michael Whitfill
  • Publication number: 20190298780
    Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.
    Type: Application
    Filed: September 5, 2018
    Publication date: October 3, 2019
    Inventor: Travis Michael Whitfill
  • Publication number: 20190256935
    Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 22, 2019
    Inventors: Travis Michael Whitfill, Ming-De Deng, David Richard Dodds
  • Publication number: 20190040116
    Abstract: The present disclosure provides, inter alia, engineered microbes expressing recombinant LEKTI domains that are effective to treat or ameliorate the symptoms of Netherton Syndrome. In certain embodiments, compositions, methods, and kits are provided comprising LEKTI domain expressing microbes.
    Type: Application
    Filed: June 15, 2018
    Publication date: February 7, 2019
    Inventors: Travis Michael Whitfill, Azim Momin Munivar
  • Publication number: 20180161380
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Application
    Filed: May 28, 2015
    Publication date: June 14, 2018
    Inventors: Azim Momin Munivar, Travis Michael Whitfill